Evidence map›Paper›PMID 35144840›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2022

KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.

Amy K Mottl, Radica Alicic, Christos Argyropoulos, Frank C Brosius, Michael Mauer, Mark Molitch, Robert G Nelson, Leigh Perreault, Susanne B Nicholas

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. New kidneys, old risks: cardiovascular challenges after transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Amy K MottlUniversity of North Carolina Kidney Center, University of North Carolina Kidney Center School of Medicine, Chapel Hill, North Carolina. Electronic address: amy_mottl@med.unc.edu.
Radica AlicicProvidence Medical Research Center, Providence Health Care, Spokane, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
Christos ArgyropoulosDivision of Nephrology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
Frank C BrosiusDepartment of Medicine, University of Arizona, Tucson, Arizona; Departments of Internal Medicine and Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan.
Michael MauerDepartments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota.
Mark MolitchDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Robert G NelsonNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.
Leigh PerreaultDivision of Endocrinology, Metabolism and Diabetes Affiliate, Center for Global Health, University of Colorado Anschutz Medical Campus and Colorado School of Public Health, Aurora, Colorado.
Susanne B NicholasDivisions of Nephrology and Endocrinology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
National Institute of Diabetes and Digestive and Kidney Diseases · USNorthwestern University · USProvidence Health & Services · USUniversity of California, Los Angeles · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan–Ann Arbor · USUniversity of Minnesota · USUniversity of New Mexico · US

Funding

Intramural NIH HHS ZIA DK069062
6 · The paper itself

Abstract

In October 2020, KDIGO (Kidney Disease: Improving Global Outcomes) published its first clinical practice guideline directed specifically to the care of patients with diabetes and chronic kidney disease (CKD). This commentary presents the views of the KDOQI (Kidney Disease Outcomes Quality Initiative) work group for diabetes in CKD, convened by the National Kidney Foundation to provide an independent expert perspective on the new guideline. The KDOQI work group believes that the KDIGO guideline takes a major step forward in clarifying glycemic targets and use of specific antihyperglycemic agents in diabetes and CKD. The purpose of this commentary is to carry forward the conversation regarding optimization of care for patients with diabetes and CKD. Recent developments for prevention of CKD progression and cardiovascular events in people with diabetes and CKD, particularly related to sodium/glucose cotransporter 2 (SGLT2) inhibitors, have filled a longstanding gap in nephrology's approach to the care of persons with diabetes and CKD. The multifaceted benefits of SGLT2 inhibitors have facilitated interactions between nephrology, cardiology, endocrinology, and primary care, underscoring the need for innovative approaches to multidisciplinary care in these patients. We now have more interventions to slow kidney disease progression and prevent or delay kidney failure in patients with diabetes and kidney disease, but methods to streamline their implementation and overcome barriers in access to care, particularly cost, are essential to ensuring all patients may benefit.

Indexed as

Diabetes MellitusNephrologyRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsKidneyHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorsblood pressure controlchronic kidney disease (CKD)commentaryDiabetesevidence-based recommendationglucagon-like peptide 1 receptor agonistsglycemic targetsguideline implementationguidelinesmetforminnephrology best practicesphysical activityprotein intakeSGLT2 inhibitorssmokingsodium intake

Identifiers

PMID35144840
PMCPMC9740752
OpenAlexW4210749107

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.